These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2009-015113-44||An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir||2014-11-18||bad-data|
|Not reported||2010-022293-14||Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-definin...||2016-03-31||due-trials|
|Ongoing||2013-002607-33||Pilot study to assess efficacy and safety of Sofosbuvir/Ledipasvir (GS-5885) fixed-dose combination with Ribavirin in NS3/4A protease inhibitor-experienced subjects with HCV genotype 1 infection and H...||not-yet-due|
|Not reported||2013-002996-16||ANRS SHS155 STIMAGO: Pilote study to evaluate the benefits and the risks of methylphenidate for the treatment of cocain dependence.||2018-06-30||due-trials|
|Not reported||2013-004571-12||Evaluation of the pharmacokinetic properties and the tolerance of raltegravir during the third trimester of pregnancy||2017-04-30||due-trials|
|Not reported||2014-000828-24||A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with an H...||2017-10-27||due-trials|
|Completed, but no date||2017-000040-17||Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral treatment taken 4 consecutive days per week versus continuous therapy 7/7 days per week in HIV-1 infected...||bad-data|
|Exempt, with results Terminated||2017-003081-27||A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic infection.||2019-07-11||not-yet-due|
|Ongoing||2019-001961-34||ANRS 173 ALTAR A randomized, open-label, phase III trial comparing a dual nucleoside analogues strategy preceded by an induction period with an integrase inhibitor based triple therapy to an immediate...||not-yet-due|
|Ongoing||2019-002818-40||A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection||not-yet-due|
|Ongoing||2019-002829-29||Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP)||not-yet-due|